JP2017518316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518316A5 JP2017518316A5 JP2016571246A JP2016571246A JP2017518316A5 JP 2017518316 A5 JP2017518316 A5 JP 2017518316A5 JP 2016571246 A JP2016571246 A JP 2016571246A JP 2016571246 A JP2016571246 A JP 2016571246A JP 2017518316 A5 JP2017518316 A5 JP 2017518316A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- complement
- seq
- acid sequence
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1410116.6A GB201410116D0 (en) | 2014-06-06 | 2014-06-06 | Method of treatment |
| GB1410116.6 | 2014-06-06 | ||
| PCT/EP2015/062742 WO2015185760A1 (en) | 2014-06-06 | 2015-06-08 | Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017518316A JP2017518316A (ja) | 2017-07-06 |
| JP2017518316A5 true JP2017518316A5 (https=) | 2019-11-14 |
| JP7045133B2 JP7045133B2 (ja) | 2022-03-31 |
Family
ID=51266841
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016571246A Active JP7045133B2 (ja) | 2014-06-06 | 2015-06-08 | Ｃ５多型を有する患者における補体媒介性疾患の治療に使用するためのオルニトドロス・モウバタ（Ｏｒｎｉｔｈｏｄｏｒｏｓ ｍｏｕｂａｔａ）補体阻害剤 |
| JP2017563314A Expired - Fee Related JP6767396B2 (ja) | 2014-06-06 | 2015-12-09 | 急性移植片対宿主病の治療に使用するためのオルニトドロス・モウバタ補体阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563314A Expired - Fee Related JP6767396B2 (ja) | 2014-06-06 | 2015-12-09 | 急性移植片対宿主病の治療に使用するためのオルニトドロス・モウバタ補体阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11052129B2 (https=) |
| EP (1) | EP3151851B1 (https=) |
| JP (2) | JP7045133B2 (https=) |
| KR (1) | KR102439717B1 (https=) |
| CN (1) | CN106659767B (https=) |
| AU (1) | AU2015270396B2 (https=) |
| BR (1) | BR112016028446A2 (https=) |
| CA (1) | CA2951175A1 (https=) |
| DK (2) | DK3151851T3 (https=) |
| ES (2) | ES2906630T3 (https=) |
| GB (1) | GB201410116D0 (https=) |
| IL (1) | IL249237B (https=) |
| MX (1) | MX382757B (https=) |
| PL (2) | PL3151851T3 (https=) |
| RU (1) | RU2700932C2 (https=) |
| WO (1) | WO2015185760A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410116D0 (en) | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| CA2988313A1 (en) * | 2015-06-08 | 2016-12-15 | Volution Immuno Pharmaceuticals Sa | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease |
| GB201602802D0 (en) * | 2016-02-17 | 2016-03-30 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| EP3464351A1 (en) * | 2016-06-07 | 2019-04-10 | Novartis AG | Anti-c5 antibody for treating patients with complement c5 polymorphism |
| SE540754C2 (en) * | 2016-11-30 | 2018-10-30 | Ikea Supply Ag | Molding of fiber blanks into three-dimensional fiber block |
| ES2945433T3 (es) | 2017-04-21 | 2023-07-03 | Volution Immuno Pharmaceuticals Sa | Coversina para el tratamiento de enfermedades ampollares autoinmunes |
| CN110831617A (zh) * | 2017-04-21 | 2020-02-21 | 沃卢申伊缪诺制药公司 | 用于治疗瘢痕性眼部发炎性病症的Coversin |
| WO2019186084A1 (en) * | 2018-03-26 | 2019-10-03 | The University Of Liverpool | Anti-complement histones |
| US20220047673A1 (en) * | 2018-09-10 | 2022-02-17 | Volution Immuno Pharmaceuticals Sa | Coversin for Use in the Treatment of Rheumatic Diseases |
| GB201905810D0 (en) * | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| GB202218084D0 (en) | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
| GB202408081D0 (en) | 2024-06-06 | 2024-07-24 | Volution Immuno Pharmaceuticals Sa | Methods of removing impurities |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050054033A9 (en) * | 1995-08-30 | 2005-03-10 | Human Genome Sciences, Inc. | Methods and compositions for treating and preventing infection using human interferon regulatory factor 3 |
| JP4772667B2 (ja) | 2003-06-02 | 2011-09-14 | エヴォルーテック・リミテッド | 補体阻害剤 |
| GB0312619D0 (en) * | 2003-06-02 | 2003-07-09 | Evolutec Ltd | Complement inhibitors |
| GB0518443D0 (en) * | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| PL2061501T3 (pl) | 2006-09-08 | 2016-01-29 | Volution Immuno Pharmaceuticals Sa | Sposób leczenia zaburzeń oddechowych |
| GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| GB0802116D0 (en) | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| GB0906779D0 (en) | 2009-04-20 | 2009-06-03 | Natural Environment Res Council | Composition |
| AU2011204483B2 (en) * | 2010-01-08 | 2016-02-11 | Volution Immuno Pharmaceuticals Sa | EV576 for use in the treatment of viral infections of the respiratory tract |
| TW201418707A (zh) * | 2012-09-21 | 2014-05-16 | Alexion Pharma Inc | 補體組分ｃ５拮抗劑之篩選分析 |
| GB201410116D0 (en) | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| ES2945433T3 (es) | 2017-04-21 | 2023-07-03 | Volution Immuno Pharmaceuticals Sa | Coversina para el tratamiento de enfermedades ampollares autoinmunes |
-
2014
- 2014-06-06 GB GBGB1410116.6A patent/GB201410116D0/en not_active Ceased
-
2015
- 2015-06-08 RU RU2016151179A patent/RU2700932C2/ru active
- 2015-06-08 EP EP15728491.0A patent/EP3151851B1/en active Active
- 2015-06-08 MX MX2016016139A patent/MX382757B/es unknown
- 2015-06-08 KR KR1020167036998A patent/KR102439717B1/ko active Active
- 2015-06-08 AU AU2015270396A patent/AU2015270396B2/en not_active Ceased
- 2015-06-08 ES ES15728491T patent/ES2906630T3/es active Active
- 2015-06-08 US US15/315,136 patent/US11052129B2/en active Active
- 2015-06-08 DK DK15728491.0T patent/DK3151851T3/da active
- 2015-06-08 BR BR112016028446A patent/BR112016028446A2/pt active Search and Examination
- 2015-06-08 PL PL15728491T patent/PL3151851T3/pl unknown
- 2015-06-08 JP JP2016571246A patent/JP7045133B2/ja active Active
- 2015-06-08 WO PCT/EP2015/062742 patent/WO2015185760A1/en not_active Ceased
- 2015-06-08 CN CN201580040646.5A patent/CN106659767B/zh active Active
- 2015-06-08 CA CA2951175A patent/CA2951175A1/en active Pending
- 2015-12-09 DK DK15807907.9T patent/DK3302519T3/da active
- 2015-12-09 PL PL15807907T patent/PL3302519T3/pl unknown
- 2015-12-09 US US15/577,906 patent/US20180193417A1/en not_active Abandoned
- 2015-12-09 ES ES15807907T patent/ES2906632T3/es active Active
- 2015-12-09 JP JP2017563314A patent/JP6767396B2/ja not_active Expired - Fee Related
-
2016
- 2016-11-27 IL IL249237A patent/IL249237B/en active IP Right Grant
-
2021
- 2021-05-28 US US17/333,675 patent/US20210283221A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017518316A5 (https=) | ||
| Ma et al. | Significance of complement system in ischemic stroke: a comprehensive review | |
| Herz et al. | Myeloid cells in the central nervous system | |
| Prinz et al. | Microglia: unique and common features with other tissue macrophages | |
| Korn et al. | T cell responses in the central nervous system | |
| Couillin et al. | STING signaling and sterile inflammation | |
| JP6931330B2 (ja) | Ｔｐｐ１配合物及びｃｌｎ２疾患を治療するための方法 | |
| JP2018516944A5 (https=) | ||
| JP2018520646A5 (https=) | ||
| US20240100081A1 (en) | Compositions and methods for treating age-related macular degeneration and geographic atrophy | |
| ATE551350T1 (de) | Verfahren und reagenzien zur behandlung und diagnose von gefässerkrankungen und altersbedingter makuladegeneration | |
| Parajuli et al. | Strategies for manipulating microglia to determine their role in the healthy and diseased brain | |
| Vonbrunn et al. | Complement Inhibition in Kidney Transplantation: Where Are We Now? E. Vonbrunn et al. | |
| Ben-Zeev et al. | Devastating recurrent brain ischemic infarctions and retinal disease in pediatric patients with CD59 deficiency | |
| Hagemann et al. | Homozygous Smpd1 deficiency aggravates brain ischemia/reperfusion injury by mechanisms involving polymorphonuclear neutrophils, whereas heterozygous Smpd1 deficiency protects against mild focal cerebral ischemia | |
| Suresh et al. | Modulation of microglia activation and Alzheimer's disease: CX3 chemokine ligand 1/CX3CR and P2X: 7: R signaling | |
| JP2019521105A5 (https=) | ||
| JP7428404B2 (ja) | Ｇｓｘ１を使用した脊髄損傷（ｓｃｉ）および脳損傷の処置 | |
| Claeys et al. | Epilepsy and migraine in a patient with Urbach–Wiethe disease | |
| CN109966488A (zh) | 周围神经的IgG刺激髓鞘再生 | |
| US20210121539A1 (en) | Methods and compositions for modulating myeloperoxidase (mpo) expression | |
| Rajan et al. | Snake venom-derived peptides as prospective pharmacological tools: recent trends | |
| JP2015522601A5 (https=) | ||
| Loh et al. | Detrimental roles of innate immune cells in neuromyelitis optica spectrum disorder: Pathogenesis and therapeutic targeting | |
| US20170145055A1 (en) | Peptide inhibitors of caspase 2 activation |